Rating Change
Guggenheim analysts reiterated a Buy rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) on July 28, 2026.
reiterateNASDAQ:KYMR
Guggenheim Reiterates Buy Rating on Kymera Therapeutics, Inc. (KYMR)
Rating Change Guggenheim analysts reiterated a Buy rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) on July 28, 2026. Market Context Kymera Therapeutics, Inc.
Market Context
Kymera Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $106.47 with a market capitalization of $6.3B.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Kymera Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Kymera Therapeutics, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 28, 2026 | Guggenheim | Buy | N/A |
| Jul 16, 2026 | Mizuho | Outperform | N/A |
| Jul 13, 2026 | RBC Capital | Sector Perform | N/A |
| Jun 30, 2026 | B of A Securities | Buy | N/A |
| Jun 29, 2026 | B. Riley Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KYMR Stock Page
Frequently Asked Questions
What does a Buy rating mean for KYMR?
A Buy rating from Guggenheim reflects the analyst's outlook on Kymera Therapeutics, Inc. (NASDAQ:KYMR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KYMR forecast page.